Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRM1 | P35372 | 3/20 | 0.47 |
| ▸ | ADRA1D | P25100 | 2/20 | 0.42 |
| ▸ | ADRA1A | P35348 | 2/20 | 0.42 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.42 |
| ▸ | CA12 | O43570 | 1/20 | 0.41 |
| ▸ | CA1 | P00915 | 1/20 | 0.41 |
| ▸ | CA2 | P00918 | 1/20 | 0.41 |
| ▸ | CA9 | Q16790 | 1/20 | 0.41 |
| ▸ | ADRA1B | P35368 | 1/20 | 0.40 |
| ▸ | MLYCD | O95822 | 1/20 | 0.39 |
| ▸ | SCD | O00767 | 1/20 | 0.38 |
| ▸ | OXTR | P30559 | 1/20 | 0.38 |
| ▸ | AVPR1A | P37288 | 1/20 | 0.38 |
| ▸ | OPRL1 | P41146 | 2/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL314945 | 0.91 | OPRM1 (0.47) | OPRM1OPRD1CA12CA1CA2 | |
| SCHEMBL3604273 | 0.72 | OPRM1 (0.59) | OPRM1OPRD1CA12CA1CA2 | |
| SCHEMBL315782 | 0.69 | CNR1 (0.54) | OPRM1ADRA1DADRA1AOPRD1ADRA1B | |
| SCHEMBL6298824 | 0.69 | OPRM1 (0.55) | OPRM1ADRA1DADRA1AOPRD1CA12 | |
| SCHEMBL504355 | 0.68 | OPRM1 (0.70) | OPRM1OPRD1CA12CA1CA2 | |
| SCHEMBL9073266 | 0.67 | ADRB1 (0.53) | OXTRAVPR1AALDH1A1 | |
| SCHEMBL1310091 | 0.67 | KMT2A (0.67) | OPRM1CA12CA1CA2CA9 | |
| SCHEMBL15963271 | 0.66 | OPRM1 (0.59) | OPRM1OPRD1CA12CA1CA2 | |
| Hydrochloric Acid SCHEMBL3595890 | 0.66 | OPRM1 (0.73) | OPRM1OPRD1 | |
| SCHEMBL8350406 | 0.66 | OPRM1 (0.81) | OPRM1ADRA1DADRA1AOPRD1ADRA1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8093400-B2 | Compounds useful in therapy | PFIZER INC. (US) | 2012-01-10 | — | — | US | disclosed |
| US-20100317652-A1 | Compounds Useful In Therapy | PFIZER INC | 2010-12-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100317652-A1 | Compounds Useful In Therapy | AVPR1A, AVPR1B, AVPR2 | OPRM1 60/4885ADRA1D 108/4885ADRA1A 50/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.